{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:29:15Z","timestamp":1792787355683,"version":"4.5.0"},"reference-count":180,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Disease Overview<\/jats:title>\n                    <jats:p>Marginal zone lymphoma (MZL) is a heterogeneous group of indolent mature B\u2010cell neoplasms with classically three major subtypes: nodal, splenic, and extranodal MZL of mucosa\u2010associated lymphoid tissue (MALT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis<\/jats:title>\n                    <jats:p>Diagnosis and disease evaluation of MZL is further advanced by the use of genomic testing and PET\/CT with\u00a0emerging evidence for the use of circulating tumor DNA. The RECLASS classification system proposed a hierarchical\u00a0approach to classifying MZL while the FIL\u2010NF10 investigators introduced a fourth MZL subtype, disseminated MZL. Though the prognosis of MZL varies between subtypes and stages, the MZL IPI and FLIPI24 indices can be used for prognostication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Treatment<\/jats:title>\n                    <jats:p>Frontline treatment of MZL varies between localized disease and advanced\u2010stage diseases. The former favor\u00a0the use of local therapies such as radiotherapy and anti\u2010microbial in certain subtypes with a selective role of rituximab\u00a0monotherapy. The latter requires systemic immunotherapy\u2009\u00b1\u2009chemotherapy with emerging data for cytotoxic\u2010free and covalent Bruton tyrosine kinase inhibitor (cBTKi)\u2010based regimens. cBTKi and immunomodulators are established in relapsed\/refractory MZL, while data for antibody\u2010drug conjugates, T\u2010cell engagers, and potentially CAR T\u2010cell therapies are maturing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ajh.70289","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:56:02Z","timestamp":1774256162000},"page":"1320-1340","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management"],"prefix":"10.1002","volume":"101","author":[{"given":"Wan Danial","family":"Noor","sequence":"first","affiliation":[{"name":"Department of Haematology, Sir Charles Gairdner Hospital  Nedlands Australia"},{"name":"Linear Clinical Research  Nedlands Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Department of Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital  Melbourne Australia"},{"name":"University of Melbourne  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Yoon","family":"Cheah","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sir Charles Gairdner Hospital  Nedlands Australia"},{"name":"Linear Clinical Research  Nedlands Australia"},{"name":"Medical School University of Western Australia  Nedlands Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265532487"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.07.002"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27058"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.010"},{"key":"e_1_2_11_6_1","unstructured":"J. A.FerryandM. Q.Du \u201cMarginal Zone Lymphoma: Introduction \u201d2024 https:\/\/tumourclassification.iarc.who.int\/chaptercontent\/63\/126."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.21037\/aol-20-28"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102592"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70232"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_598"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02309.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPZQ1GXBBNG8OG"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-624296"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.378"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP6ZODWV1CIDME"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.083386"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqy144"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.07.149"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012386"},{"key":"e_1_2_11_21_1","unstructured":"I. S.Lossos L.Biral D.Thakkar et\u00a0al. \u201cGenomic and Transcriptomic Landscape of Extranodal Marginal Zone Lymphoma \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/298635."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-696757"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2016.09.014"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.09.005"},{"issue":"71","key":"e_1_2_11_25_1","first-page":"253","article-title":"Splenic Diffuse Red Pulp Small\u2010B Cell Lymphoma: Toward the Emergence of a New Lymphoma Entity","volume":"13","author":"Traverse\u2010Glehen A.","year":"2012","journal-title":"Discovery Medicine"},{"issue":"7","key":"e_1_2_11_26_1","first-page":"601","article-title":"Absence of Cyclin D1 Protein Expression in Splenic Marginal Zone Lymphoma","volume":"11","author":"Savilo E.","year":"1998","journal-title":"Modern Pathology"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405068"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207886"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157194"},{"key":"e_1_2_11_30_1","doi-asserted-by":"crossref","unstructured":"P.Vodicka M.Maurer M.Masar et\u00a0al. \u201cFLIPI24 as a Prognostic Model in Marginal Zone Lymphoma: Results From an International Multi\u2010Cohort Analysis \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/300181.","DOI":"10.1182\/blood-2025-1826"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020984"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001088"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.237990"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27712"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2578"},{"key":"e_1_2_11_37_1","doi-asserted-by":"crossref","unstructured":"L.Ceriani S.Luminari A. S.Cottereau et\u00a0al. \u201cUtility of 18F\u2010FDG PET\/CT for Response Assessment in Marginal Zone Lymphomas: Preliminary Results of the IELSG44 International Study \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/293375.","DOI":"10.1182\/blood-2025-1810"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05683-2"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204458"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019294"},{"issue":"3","key":"e_1_2_11_41_1","article-title":"Nodal Marginal Zone Lymphoma: Mutational Analysis, Gene Expression Profile, and Differential Diagnosis From Other Small b\u2010Cell Lymphomas","volume":"43","author":"Borgmann V.","year":"2025","journal-title":"Hematology\/Oncology"},{"issue":"3","key":"e_1_2_11_42_1","article-title":"IgHV and tp53 Mutational Status at Diagnosis May Have Impact on Outcome in Patients With Splenic Marginal Zone Lymphoma","volume":"43","author":"Cappello E.","year":"2025","journal-title":"Hematology\/Oncology"},{"issue":"3","key":"e_1_2_11_43_1","article-title":"Genetic Profiling OF Marginal Zone Lymphoma in ctDNA at Diagnosis and During Follow\u2010Up: Diagnostic and Prognostic Implications","volume":"43","author":"Diez\u2010Feij\u00f3o R.","year":"2025","journal-title":"Hematology\/Oncology"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00138"},{"issue":"3","key":"e_1_2_11_45_1","article-title":"Histological Transformation in Marginal Zone Lymphoma (Malt, Nodal and Splenic): Risk, Clinical Features and Outcome","volume":"43","author":"Correa J. G.","year":"2025","journal-title":"Hematology\/Oncology"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00903-w"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009587"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202721"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.05.004"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14306"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00668"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i11.2751"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-624304"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.096420"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100714"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3078"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00133-9"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202424"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17411"},{"issue":"3","key":"e_1_2_11_60_1","article-title":"Multicenter Retrospective Cohort Study of 805 Patients With Ocular Adnexal Marginal Zone b\u2010Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group","volume":"43","author":"Li X.","year":"2025","journal-title":"Hematology\/Oncology"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-486522"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-7-8"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2005.11.005"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172845"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199002"},{"issue":"3","key":"e_1_2_11_66_1","article-title":"Real World Outcomes of the First\u2010Line Treatment of Localized Extranodal Marginal Zone Lymphoma of Ocular Adnexa or Orbit","volume":"43","author":"\u010eura\u0161 J.","year":"2025","journal-title":"Hematology\/Oncology"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12742"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00004313"},{"issue":"4","key":"e_1_2_11_69_1","first-page":"177","article-title":"A Retrospective International Study on Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT Lymphoma) on Behalf of International Extranodal Lymphoma Study Group (IELSG): Retrospective Analysis on BALT Lymphoma","volume":"34","author":"Sammassimo S.","year":"2016","journal-title":"Hematology\/Oncology"},{"key":"e_1_2_11_70_1","doi-asserted-by":"crossref","unstructured":"K.Wu N.Adhikari A.Sanghvi et\u00a0al. \u201cIncreasing Incidences in Primary Lung Marginal Zone Lymphoma: A SEER Database Analysis \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/302286.","DOI":"10.1182\/blood-2025-3610"},{"issue":"3","key":"e_1_2_11_71_1","article-title":"Systemic Malt Lymphoma With Pulmonary Involvement: A Multi\u2010Institutional Observational Study in Japan","volume":"43","author":"Suzuki K.","year":"2025","journal-title":"Hematology\/Oncology"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003213"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101648"},{"issue":"3","key":"e_1_2_11_74_1","first-page":"709","article-title":"Watch\u2010and\u2010Wait or Immediate Immunotherapy\/Immunochemotherapy in Patients With Phase IE Primary Pulmonary MALT Lymphoma? A Multicenter Retrospective Study","volume":"100","author":"Yan W.","year":"2021","journal-title":"Annals of Hematology"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0180"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/jop.13168"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1644333"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3746"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.047"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1933479"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1159\/000502204"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01478"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.17.624"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2732"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1218006"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.01.009"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-04052-1"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1791849"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1686501"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2015766"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031887"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70036-1"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11893"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714667"},{"issue":"3","key":"e_1_2_11_96_1","article-title":"Long\u2010Term Benefit and Molecular Features of Patients With Hcv\u2010Associated Indolent Lymphomas Treated With Direct\u2010Acting Antivirals: 6\u2010Year Follow\u2010Up of the Fil_Bart Study","volume":"43","author":"Merli M.","year":"2025","journal-title":"Hematology\/Oncology"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624312"},{"key":"e_1_2_11_98_1","doi-asserted-by":"crossref","unstructured":"O.Ogbue J.Zhou O.Adeoye et\u00a0al. \u201cReal\u2010World Treatment Patterns and Survival in Splenic Marginal Zone Lymphoma: A National Analysis in the Rituximab Era \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/296267.","DOI":"10.1182\/blood-2025-1813"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2022.06.002"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.1583.1583"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18912"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160073"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.6994"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)00021-0"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-795302"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.046885"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006844"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15641"},{"issue":"7","key":"e_1_2_11_111_1","first-page":"2297","article-title":"Bendamustine and Rituximab as First\u2010Line Treatment for Symptomatic Splenic Marginal Zone Lymphoma: Long\u2010Term Outcome and Impact of Early Unmeasurable Minimal Residual Disease Attainment From the BRISMA\/IELSG36 Phase II Study","volume":"109","author":"Iannitto E.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2334"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.40_2630"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.696"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15843"},{"key":"e_1_2_11_116_1","doi-asserted-by":"crossref","unstructured":"A.Olszewski M.Matasar S.Huntington et\u00a0al. \u201cMosunetuzumab With Response\u2010Driven Lenalidomide Augmentation Achieves High Response Rates and Immune Reprogramming in Untreated Follicular and Marginal Zone Lymphoma: A Multicenter Phase 2 Trial \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/290670.","DOI":"10.1182\/blood-2025-1003"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-193022"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.7063"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)02460-7"},{"key":"e_1_2_11_120_1","doi-asserted-by":"crossref","unstructured":"R.Lynch C.Poh M.Shadman et\u00a0al. \u201cResponse\u2010Adapted Treatment With Mosunetuzumab With or Without Obinutuzumab and Polatuzumab Vedotin in Treatment Na\u00efve Follicular and Marginal Zone Lymphoma: Final Results and Phased\u2010seq MRD Analysis \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/298283.","DOI":"10.1182\/blood-2025-3591"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_591"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011698"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010298"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-211730"},{"key":"e_1_2_11_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70094_254"},{"key":"e_1_2_11_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_52"},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_589"},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70094_255"},{"issue":"3","key":"e_1_2_11_129_1","article-title":"Orelabrutinib Combined With Anti\u2010cd20 Monoclonal Antibodies Is Highly Effective and Well Tolerated as First\u2010Line Therapy for Marginal Zone b Cell Lymphoma","volume":"43","author":"Wang L.","year":"2025","journal-title":"Hematological Oncology"},{"key":"e_1_2_11_130_1","doi-asserted-by":"crossref","unstructured":"Z.Li H.Wang Z.Lin et\u00a0al. \u201cPreliminary Study Results of Orelabrutinib in Combination With Rituximab for Treatment Na\u00efve Marginal Zone Lymphoma: A Prospective Single\u2010Arm Clinical Trial \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/296057.","DOI":"10.1182\/blood-2025-3580"},{"key":"e_1_2_11_131_1","doi-asserted-by":"crossref","unstructured":"W.Wang Y.Mao J.Ruan et\u00a0al. \u201cEfficacy and Safety of Orelabrutinib Obinutuzumab and Lenalidomide in Previously Untreated Marginal Zone Lymphoma: Preliminary Results From a Prospective Single\u2010Arm Multicenter Phase Ii Study \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/299757.","DOI":"10.1182\/blood-2025-5383"},{"issue":"3","key":"e_1_2_11_132_1","article-title":"A Phase ii Study of Acalabrutinib, Lenalidomide and Rituximab in Patients With Previously Untreated Indolent b\u2010Cell Lymphoma","volume":"43","author":"Strati P.","year":"2025","journal-title":"Hematological Oncology"},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_588"},{"key":"e_1_2_11_134_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204442"},{"key":"e_1_2_11_135_1","doi-asserted-by":"crossref","unstructured":"X.Zhang Y.Lv X.Zhang et\u00a0al. \u201cOrelabrutinib Combined With Bendamustine\u2010Rituximab or Obinutuzumab Followed by Orelabrutinib Maintenance in Untreated Marginal Zone Lymphoma (Optimize): A Multicenter Single\u2010Arm Phase II Study \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/299329.","DOI":"10.1182\/blood-2025-3596"},{"key":"e_1_2_11_136_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_596"},{"key":"e_1_2_11_137_1","doi-asserted-by":"crossref","unstructured":"N.Epperla J.Sharp N.Grover et\u00a0al. \u201cEvaluation of Outcomes by Line of Therapy in Marginal Zone Lymphoma: Real\u2010World Evidence From 10 US Academic Centers \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/300793.","DOI":"10.1182\/blood-2025-4533"},{"key":"e_1_2_11_138_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_2_11_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01549-X"},{"key":"e_1_2_11_140_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-747345"},{"key":"e_1_2_11_141_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003121"},{"key":"e_1_2_11_142_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18368"},{"key":"e_1_2_11_143_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010668"},{"key":"e_1_2_11_144_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1704"},{"key":"e_1_2_11_145_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27064"},{"key":"e_1_2_11_146_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194572"},{"key":"e_1_2_11_147_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e19527"},{"key":"e_1_2_11_148_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2416577"},{"issue":"3","key":"e_1_2_11_149_1","article-title":"A Meta\u2010Analysis Investigating Response Rates of Continuous Btki Monotherapies in the Treatment of B\u2010Cell Lymphomas","volume":"43","author":"Zinzani P. L.","year":"2025","journal-title":"Hematology\/Oncology"},{"key":"e_1_2_11_150_1","unstructured":"A. M.Prat F.Martin\u2010Moro X.Guti\u00e9rrez et\u00a0al. \u201cSpanish Real\u2010Life Practice Confirms Zanubrutinib as a Safe and Effective Option in Relapsed or Refractory Marginal Zone Lymphoma: Results of a Cohort of 118 Patients on Behalf of Geltamo \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/290428."},{"key":"e_1_2_11_151_1","doi-asserted-by":"crossref","unstructured":"N.Epperla G.Shouse J.Hatfield et\u00a0al. \u201cEvaluation of Real\u2010World Outcomes With Zanubrutinib in Patients With Marginal Zone Lymphoma: Results From Multicenter Cohort Study \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/300882.","DOI":"10.1182\/blood-2025-4534"},{"issue":"3","key":"e_1_2_11_152_1","article-title":"Zanubrutinib in Relapsed\/Refractory Marginal Zone Lymphoma (r\/r Mzl): Efficacy and Safety of 101 Spanish Patients Treated in the Real\u2010World on Behalf of Geltamo","volume":"43","author":"Martin\u2010Moro F.","year":"2025","journal-title":"Hematology\/Oncology"},{"key":"e_1_2_11_153_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009412"},{"key":"e_1_2_11_154_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180048"},{"issue":"3","key":"e_1_2_11_155_1","article-title":"Nemtabrutinib in Relapsed or Refractory Marginal Zone Lymphoma: Updated Results From Cohort f of the Phase 2 Bellwave\u2010003 Study","volume":"43","author":"Tucci A.","year":"2025","journal-title":"Hematology\/Oncology"},{"key":"e_1_2_11_156_1","doi-asserted-by":"crossref","unstructured":"A.Tucci Y.Herishanu J.Dupont et\u00a0al. \u201cPhase 2 Bellwave\u2010003 Cohort F: Updated Clinical Outcomes of Nemtabrutinib in Participants With Relapsed or Refractory Marginal Zone Lymphoma \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/290967.","DOI":"10.1182\/blood-2025-1801"},{"key":"e_1_2_11_157_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008634"},{"issue":"3","key":"e_1_2_11_158_1","article-title":"Phase ii Study of Orelabrutinib Plus Obinutuzumab With or Without Chemotherapy for Marginal Zone Lymphoma Patients With High\u2010Risk Recurrence Factors","volume":"43","author":"Hu M.","year":"2025","journal-title":"Hematology\/Oncology"},{"key":"e_1_2_11_159_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7590"},{"key":"e_1_2_11_160_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016646"},{"key":"e_1_2_11_161_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199866"},{"key":"e_1_2_11_162_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178841"},{"key":"e_1_2_11_163_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174292"},{"key":"e_1_2_11_164_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"e_1_2_11_165_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200190"},{"key":"e_1_2_11_166_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_856"},{"key":"e_1_2_11_167_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.tps7094"},{"key":"e_1_2_11_168_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70094_259"},{"issue":"4","key":"e_1_2_11_169_1","first-page":"303","article-title":"The Antibody\u2010Drug Conjugate Loncastuximab Tesirine for the Treatment of Diffuse Large B\u2010Cell Lymphoma","volume":"140","author":"Calabretta E.","year":"2022","journal-title":"Blood"},{"key":"e_1_2_11_170_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70094_260"},{"key":"e_1_2_11_171_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167153"},{"key":"e_1_2_11_172_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00668"},{"key":"e_1_2_11_173_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_55"},{"key":"e_1_2_11_174_1","unstructured":"Center for Drug Evaluation Research \u201cFDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma \u201d2025 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010lisocabtagene\u2010maraleucel\u2010relapsed\u2010or\u2010refractory\u2010marginal\u2010zone\u2010lymphoma."},{"key":"e_1_2_11_175_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194632"},{"key":"e_1_2_11_176_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199154"},{"key":"e_1_2_11_177_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179508"},{"key":"e_1_2_11_178_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_115"},{"key":"e_1_2_11_179_1","doi-asserted-by":"crossref","unstructured":"C.Cheah M.Shanavas J.Chavez et\u00a0al. \u201cCaDAnCe\u2010104 an Ongoing Open\u2010Label Phase 1b\/2 Master Protocol Study of Bruton Tyrosine Kinase Degrader BGB\u201016673 in Combination With Other Agents in Patients With Relapsed\/Refractory B\u2010Cell Malignancies Category: Category: Trials in Progress Review Category: Review Category: TiP2. Trials in Progress: Lymphoid Malignancies Authors \u201d2025 https:\/\/meetings\u2010api.hematology.org\/api\/abstract\/vmpreview\/296326.","DOI":"10.1182\/blood-2025-1839"},{"key":"e_1_2_11_180_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201269"},{"issue":"3","key":"e_1_2_11_181_1","article-title":"Peptide Immunotherapy in Combination With Lenalidomide (l) and Rituximab (r) in Patients (Pts) With Follicular (Fl) and Marginal Zone Lymphoma (Mzl)","volume":"43","author":"Villasboas J. C.","year":"2025","journal-title":"Hematological Oncology"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70289","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70289","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:24:55Z","timestamp":1777965895000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":180,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/ajh.70289"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70289","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"2025-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}